Re: "The best PR for this company is FDA approval."
No one under the sun would argue this point. It's almost a tautology. The question is, when? No one knows. DR says to expect approval in Q2 of 2008. DR's published expectations have been wrong before, as we long-timers well know. There are no guarantees. What if FDA takes until Q4 2008? What then? Watch helplessly as CTGI sinks to $0.50 while praying for FDA?
In four years, O/S has doubled. Meanwhile, expenses have never been greater than currently. CSMG employs 14 full-timers in the USA and two full-timers in the Ukraine. It operates a laboratory and manufacturing facility (LTC) in a 4,410 sq. ft. facility in Goleta, California. CSMG has retained the expertise of a top Ukraine carbon sequestration scientist. There are management salaries, and a number of eminent professionals on advisory boards. Et cetera. Where is the money to pay for all of this? Right. Without revenues, sale of Rule 144 stock. A low stock price spawns increasing dilution.
Arguably, this company is a novice at promotion. The PRs are exercises in understatement and restraint almost to a fault, nay, to a fault. Laudable perhaps in former times, but not now as the company's capital needs intensify. They should at least retain a professional PR writer who knows how to gather public interest and generate market excitement.
CSMG says it has 305 shareholders. (As a penny stock it has naturally no institutional following, confirmed recently by Vickers.) Its miniscule shareholder base is testimony to a company with innate inability to rouse market interest beyond narrow perimeters despite fabulous undertakings and vast potential. No one wants to see CSMG placing loads of restricted stock at fire sale prices to sustain its considerable expenses. As things stand, that's arguably in the cards.
News 
Market Data 
Discover 
